Treatment Strategies in Endogenous Fungal Endophthalmitis

Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.

By
Arthi Venkat, MD, MS
Eleanor M. Burton, MD
January 1, 2026
7 min

Retinal Physician

Objective:

To evaluate treatment strategies and outcomes for endogenous fungal endophthalmitis (EFE) across multiple institutions from 2010 to 2023.

Approach:

Key Findings:

Endogenous endophthalmitis accounts for 5% to 10% of all endophthalmitis cases, with fungal and bacterial organisms each representing about half, highlighting the need for tailored treatment strategies.
Candida was the most frequently identified organism, while mold and culture-negative cases each accounted for approximately 20%, indicating diverse etiologies.
72% of eyes received combination systemic and intravitreal antifungals, a significant increase from previous studies, suggesting evolving treatment paradigms.
Voriconazole (34%) and fluconazole (30%) were the most frequently used initial systemic agents, reflecting current preferences in antifungal therapy.
Regional variations were noted in treatment approaches, with differences in the use of IV systemic therapy and surgical interventions, underscoring the need for region-specific guidelines.

Interpretation:

The management of EFE is complex and varies significantly by region, with systemic markers influencing treatment choices more than ocular findings. A multidisciplinary approach is essential for optimizing patient outcomes, as evidenced by the study's findings.

Limitations:

Limited explicit guidelines for managing EFE based on low-quality evidence, which may hinder optimal treatment.
No studies have evaluated intraocular penetration of oral or IV fluconazole or voriconazole in inflamed or infected eyes, raising concerns about treatment efficacy.

Conclusion:

A comprehensive approach considering ocular involvement is crucial for optimizing treatment outcomes in EFE, despite the lack of definitive evidence favoring one systemic therapy route over another.